SunTrust Banks Initiates Coverage on BioDelivery Sciences International (BDSI)

Equities research analysts at SunTrust Banks began coverage on shares of BioDelivery Sciences International (NASDAQ:BDSI) in a research report issued on Tuesday, Marketbeat reports. The firm set a “buy” rating and a $7.00 price target on the specialty pharmaceutical company’s stock. SunTrust Banks’ price objective suggests a potential upside of 32.83% from the stock’s previous close.

BDSI has been the topic of several other reports. Cantor Fitzgerald set a $5.00 price objective on shares of BioDelivery Sciences International and gave the stock a “buy” rating in a research note on Thursday, December 27th. Zacks Investment Research lowered shares of BioDelivery Sciences International from a “buy” rating to a “hold” rating in a research note on Friday, January 18th. BidaskClub upgraded shares of BioDelivery Sciences International from a “sell” rating to a “hold” rating in a research note on Friday, December 7th. Finally, HC Wainwright restated a “buy” rating and set a $6.00 price objective on shares of BioDelivery Sciences International in a research note on Friday, March 15th. Three analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $5.79.

BioDelivery Sciences International stock opened at $5.27 on Tuesday. The stock has a market cap of $350.49 million, a PE ratio of -7.22 and a beta of 0.45. BioDelivery Sciences International has a fifty-two week low of $1.70 and a fifty-two week high of $5.36. The company has a current ratio of 3.07, a quick ratio of 2.82 and a debt-to-equity ratio of 1.74.

In related news, Director Mark A. Sirgo sold 10,000 shares of the company’s stock in a transaction dated Thursday, December 27th. The shares were sold at an average price of $2.91, for a total value of $29,100.00. Following the transaction, the director now owns 2,489,542 shares in the company, valued at approximately $7,244,567.22. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Francis E. Odonnell, Jr. sold 23,000 shares of the company’s stock in a transaction dated Friday, March 1st. The shares were sold at an average price of $5.07, for a total transaction of $116,610.00. Following the completion of the transaction, the director now owns 544,187 shares in the company, valued at approximately $2,759,028.09. The disclosure for this sale can be found here. In the last quarter, insiders sold 50,175 shares of company stock worth $215,265. 13.26% of the stock is owned by company insiders.

A number of institutional investors and hedge funds have recently made changes to their positions in BDSI. Advisor Group Inc. grew its stake in BioDelivery Sciences International by 56.3% in the 4th quarter. Advisor Group Inc. now owns 10,943 shares of the specialty pharmaceutical company’s stock valued at $40,000 after buying an additional 3,943 shares during the last quarter. Squarepoint Ops LLC bought a new stake in BioDelivery Sciences International in the 4th quarter valued at about $147,000. Worth Venture Partners LLC bought a new stake in BioDelivery Sciences International in the 3rd quarter valued at about $167,000. Raymond James & Associates boosted its holdings in BioDelivery Sciences International by 14.9% in the 4th quarter. Raymond James & Associates now owns 46,211 shares of the specialty pharmaceutical company’s stock valued at $171,000 after purchasing an additional 6,000 shares during the period. Finally, Dimensional Fund Advisors LP bought a new stake in BioDelivery Sciences International in the 3rd quarter valued at about $255,000. Institutional investors and hedge funds own 56.98% of the company’s stock.

About BioDelivery Sciences International

BioDelivery Sciences International, Inc is a pharmaceutical company, which engages in the development and commercialization of new applications of approved therapeutics to address important unmet medical needs. It focuses on pharmaceutical products in the areas of pain management and addiction. The company was founded on January 6, 1997 and is headquartered in Raleigh, NC.

Read More: Why do companies pay special dividends?

Analyst Recommendations for BioDelivery Sciences International (NASDAQ:BDSI)

Receive News & Ratings for BioDelivery Sciences International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International and related companies with MarketBeat.com's FREE daily email newsletter.



Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit